TY - JOUR
T1 - Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia
AU - Hoshino, K.
AU - Quintás-Cardama, A.
AU - Yang, H.
AU - Sanchez-Gonzalez, B.
AU - Garcia-Manero, G.
N1 - Funding Information:
This work was funded in part by Grants CA100067 and CA105771 from the NCI, and the University of Texas MD Anderson Cancer Center’s Physician-Scientist Program Award funded by the Commonwealth Cancer Foundation for Research (G G-M). We thank Claritza Santos-Malave, a visiting student from the University of Puerto Rico, for technical assistance, and to Drs N Donato and M Beran for sharing cell lines. DNA sequencing was performed at a core facility at the University of Texas MD Anderson Cancer funded by Core Grant CA16672.
PY - 2007/5
Y1 - 2007/5
N2 - Hck and Lyn are required in Philadelphia chromosome (Ph) positive acute lymphocytic leukemia (ALL). Here, we present evidence that the promoter CpG island of Hck, but not of Lyn, is aberrantly methylated in leukemia. Hck promoter DNA methylation was detected in 13 out of 23 (56.5%) hematopoietic and eight out of 10 (80%) non-hematopoietic cell lines, but not in normal controls. Treatment with 5-aza-2′-deoxycytidine induced demethylation and restoration of Hck mRNA and protein expression. Hck methylation (≥15%) was detected in nine out of 44 (20%) patients with Ph negative ALL, and in one out 16 (6%) patients with Ph positive ALL, but not in patients with AML or chronic myelogenous leukemia. In this subset of patients, low levels of Hck methylation (10-15%) were observed in 26-30% of patients. Lyn methylation was observed in three out of 28 (10.7%) cell lines, but only in one out of 71 (1.4%) patients. Patients with Ph negative ALL and Hck methylation had a poorer prognosis. These data indicate that Hck may have tumor suppressor properties in BCR-ABL negative leukemia.
AB - Hck and Lyn are required in Philadelphia chromosome (Ph) positive acute lymphocytic leukemia (ALL). Here, we present evidence that the promoter CpG island of Hck, but not of Lyn, is aberrantly methylated in leukemia. Hck promoter DNA methylation was detected in 13 out of 23 (56.5%) hematopoietic and eight out of 10 (80%) non-hematopoietic cell lines, but not in normal controls. Treatment with 5-aza-2′-deoxycytidine induced demethylation and restoration of Hck mRNA and protein expression. Hck methylation (≥15%) was detected in nine out of 44 (20%) patients with Ph negative ALL, and in one out 16 (6%) patients with Ph positive ALL, but not in patients with AML or chronic myelogenous leukemia. In this subset of patients, low levels of Hck methylation (10-15%) were observed in 26-30% of patients. Lyn methylation was observed in three out of 28 (10.7%) cell lines, but only in one out of 71 (1.4%) patients. Patients with Ph negative ALL and Hck methylation had a poorer prognosis. These data indicate that Hck may have tumor suppressor properties in BCR-ABL negative leukemia.
UR - http://www.scopus.com/inward/record.url?scp=34247610968&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247610968&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404615
DO - 10.1038/sj.leu.2404615
M3 - Article
C2 - 17344919
AN - SCOPUS:34247610968
SN - 0887-6924
VL - 21
SP - 906
EP - 911
JO - Leukemia
JF - Leukemia
IS - 5
ER -